Homestead Advisers Corp Has $4.52 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Homestead Advisers Corp raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 39.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 50,500 shares of the medical equipment provider's stock after buying an additional 14,300 shares during the quarter. Homestead Advisers Corp owned 0.07% of Lantheus worth $4,518,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB acquired a new position in shares of Lantheus in the third quarter worth $25,000. Kestra Investment Management LLC acquired a new position in Lantheus in the 4th quarter worth about $27,000. UMB Bank n.a. raised its stake in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after purchasing an additional 134 shares in the last quarter. World Investment Advisors LLC acquired a new stake in shares of Lantheus during the 3rd quarter valued at about $60,000. Finally, Parkside Financial Bank & Trust grew its stake in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Up 1.7 %

LNTH traded up $1.65 during trading on Monday, reaching $97.81. 178,382 shares of the company's stock were exchanged, compared to its average volume of 939,047. Lantheus Holdings, Inc. has a fifty-two week low of $58.16 and a fifty-two week high of $126.89. The company has a market capitalization of $6.70 billion, a P/E ratio of 16.28 and a beta of 0.38. The business has a 50 day moving average price of $93.21 and a 200 day moving average price of $96.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,109 shares of company stock worth $6,110,806 in the last 90 days. Corporate insiders own 1.50% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. JMP Securities restated a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial raised their target price on Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. B. Riley decreased their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Lantheus presently has an average rating of "Moderate Buy" and a consensus price target of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.